



Allergologia et immunopathologia

www.elsevier.es/ai



RESEARCH LETTER

Delayed hypersensitivity challenged by subcutaneous Bemiparin

Bemiparin delayed type hypersensitivity

To the Editor:

Low-molecular-weight heparins (LMWHs) are now routinely used in protocols for the treatment of suspected myocardial infarction, unstable angina, deep vein thrombosis and pulmonary embolus.

A 65-year-old woman with contact dermatitis to nickel developed infiltrated itchy and big eczematous plaques at the subcutaneous injection sites on the lower abdomen, one week after beginning treatment with Bemiparin due to an orthopaedic surgery. This drug was changed for Enoxaparin, tolerated during her admission, but days later she complained of the same lesions.

In order to identify an alternative heparin and once informed consent had been obtained, patch, intradermal, and subcutaneous tests were performed with a panel of unfractionated heparin (UFH), LMWHs and Fondaparinux.

Patch tests performed with Sodic Heparin, Bemiparin, Enoxaparin, Dalteparin, Nadroparin, Tinzaparin and Fondaparinux were negative, except for Bemiparin which was positive at 96 hours (eczematous plaque in application area) and less clear for Enoxaparin. Intradermal tests with Sodic Heparin, Enoxaparin, Dalteparin, Nadroparin, Tinzaparin and Fondaparinux were negative except for Enoxaparin which was positive at 24 hours.

Due to the necessity of anticoagulant treatment, subcutaneous challenge test was developed with Nadroparin, Dalteparin, Tinzaparin and Sodic Heparin, which were positive (itchy infiltrates and erythematous plaques hours later). However, subcutaneous challenge test with Fondaparinux was negative.

Heparins are complex mixtures of mucopolysaccharides produced from porcine or bovine intestines and lungs. Molecular weight differentiates UFHs (10–20 kDa) from LMWHs (4–6 kDa)¹.

Heparin eczema-like plaques result due to the binding of the heparin molecule to dermal protein, triggering a delayed-type hypersensitivity (DTH) reaction.²

The consulted bibliography shows the wide variability of heparin cross-reactivity, among LMWHs themselves and also

between LMWHs and UFHs,^{1,3–6} so all heparins should be avoided in such individuals.

According to what Ludwig published⁷, a substance with a very low molecular weight is believed to reduce the frequency of DTH reactions to LMWH. Bemiparin (3.7 kDa) is supposed to be a suitable alternative when there is DTH reaction⁵. In our patient Bemiparin probably caused DTH reaction.

The study by Grims⁵ did not show a correlation between molecular weight and the frequency of cross-reactivity, and reported the first cases of cross-reactivity of Bemiparin with other LMWHs. In this study Fondaparinux was well tolerated, as happened to our patient.

Grims⁵ also found a particularly high cross-reactivity between Enoxaparin and Bemiparin. He explains this cross-reactivity because all patients had primarily been sensitized to Enoxaparin and cross-reactivity to Bemiparin was highest with Enoxaparin probably due to a similar chemical structure. We think our patient was sensitized first to Bemiparin and later, due to the cross-reactivity between them, she developed the eczematous plaques with Enoxaparin.

The use of a substance with an entirely different chemical structure such as recombinant hirudin (Lepidurin) or Fondaparinux (17 kDa) nearly excludes cross-reactivity with LMWHs,^{5,6} but they must be probed because there are described cases in the literature of type IV reaction to Fondaparinux^{2,8} and anaphylactic reactions to Lepidurin.⁹

We challenged with other LMWHs that had negative patch or intradermal tests to get an alternative and sure treatment and, with the exception of Fondaparinux, all proved positive. So patch and intradermal tests were partially useful to find an alternative drug, with subcutaneous challenge test being the best means of detecting the entire spectrum of sensitisation.^{4,5}

We have found in the literature some reports about the intravenous heparin tolerance in patients with DTH reaction.^{10,11,12} Gaigl et al.¹² published a prospective study in 2004 in which 28 patients with a proven delayed-type hypersensitivity to subcutaneous heparin were challenged with intravenous heparin, being well tolerated for all of them. So, in case of therapeutic necessity, the shift from subcutaneous to intravenous heparin would be justified¹². A possible reason for intravenous tolerance may be the difference in antigen processing and presentation of selectively sensitized lymphocytes in the dermis.^{11,12} Trautman and Seitz¹³ in their

report, consider that, although there are some prospective studies supporting the use of intravenous administration of heparin in patients with DTH reaction, substantial doubt still exists as to whether the use of intravenous administration of heparin is really safe for all these patients.

In conclusion, we report a rare case of delayed-type hypersensitivity reaction to Bemiparin. We have demonstrated cross-reactivity between Bemiparin and Enoxaparin by patch test. Due to the possibility of cross-reactivity between heparins, before recommending an alternative heparin, an allergic study with patch, intradermal and subcutaneous challenge tests must be performed. We think that subcutaneous challenge test is necessary to confirm the tolerance of the alternative drug.

References

1. Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. *Contact Dermatitis*. 2004;49:276–80.
2. White JML, Munn SE, Seet JE, Adams N, Clement M. Eczema-like plaques secondary to enoxaparin. *Contact Dermatitis*. 2006;54:18–20.
3. Poza-Guedes P, González-Pérez R, Canto G. Different patterns of cross-reactivity in non-immediate hypersensitivity to heparins: from localized to systemic reactions. *Contact Dermatitis*. 2002;47(4):244–5.
4. Méndez J, Sanchís ME, De la Fuente R, Stolle R, Vega JM, Martínez C, et al. Delayed-type hypersensitivity to subcutaneous enoxaparin. *Allergy*. 1998;53:999–1003.
5. Grims RH, Weger W, Reiter H, Arbab E, Kränke B, Aberer W. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. *British Journal of Dermatology*. 2007;157:514–7.
6. Hohenstein E, Tsakiris D, Bircher AJ. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. *Contact Dermatitis*. 2004;51(3):149–51.
7. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. *Thromb Haemost*. 2005;94:1265–9.
8. Hirsch K, Ludwig RJ, Lindhoff-Last E, Kaufmann R, Boehncke WH. Intolerance of fondaparinux in a patient allergic to heparins. *Contact Dermatitis*. 2004;50(6):383–4.
9. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. *Circulation*. 2003;108:2062–5.
10. Maroto-Litani M, Higaki Y, Kawashima M. Cutaneous allergic reaction to heparins: subcutaneous but not intravenous provocation. *Contact Dermatitis*. 2005;52:228–30.
11. Seitz CS, Brocker EB, Trautmann A. Management of allergy to heparins in postoperative care: Subcutaneous allergy and intravenous tolerance. *Dermatology Online Journal*. 2008;14(9):4.
12. Gaigl Z, Pfeuffer P, Raith P, Bröcker EB, Trautmann A. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. *British Journal of Haematology*. 2004;128:389–92.
13. Trautmann A, Seitz C. Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. *Immunol Allergy Clin N Am*. 2009;29:469–80.

M.C. Moreno Escobosa*, M.C. Moya Quesada, S. Cruz Granados, J. Amat López

Allergy Department, Hospital Torrecárdenas, Almería, Spain

*Autor para correspondencia.

E-mail address: moreno.escobosa@terra.es (M.C. Moreno Escobosa).